Cargando…
De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163728/ https://www.ncbi.nlm.nih.gov/pubmed/37149679 http://dx.doi.org/10.1186/s12957-023-03029-2 |
_version_ | 1785037943668211712 |
---|---|
author | Du, Danwei Xie, Yangyang Li, Xiaowen Ni, Zhongkai Shi, Jinbo Huang, Hai |
author_facet | Du, Danwei Xie, Yangyang Li, Xiaowen Ni, Zhongkai Shi, Jinbo Huang, Hai |
author_sort | Du, Danwei |
collection | PubMed |
description | BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kaplan–Meier survival analyses, propensity score matching (PSM), and competing risk analyses. The predictive nomogram was then built and validated. RESULTS: Four hundred four patients with stage I–II GNEC were enrolled from the SEER database while 28 patients from Hangzhou TCM Hospital were identified as the external validation cohort. After PSM, similar 5-year cancer-specific survival was observed in two groups. The outcomes of competing risk analysis indicated a similar 5-year cumulative incidence of cancer-specific death (CSD) between the two cohorts (35.4% vs. 31.4%, p = 0.731). And there was no significant relation between chemotherapy and CSD in the multivariate competing risks regression analysis (HR, 0.79; 95% CI, 0.48–1.31; p = 0.36). Furthermore, based on the variables from the multivariate analysis, a competing event nomogram was created to assess the 1-, 3-, and 5-year risks of CSD. The 1-, 3-, and 5-year area under the receiver operating characteristic curve (AUC) values were 0.770, 0.759, and 0.671 in the training cohort, 0.809, 0.782, and 0.735 in the internal validation cohort, 0.786, 0.856, and 0.770 in the external validation cohort. Furthermore, calibration curves revealed that the expected and actual probabilities of CSD were relatively consistent. CONCLUSION: Stage I–II GNEC patients could not benefit from adjuvant chemotherapy after surgery. De-escalation of chemotherapy should be considered for stage I–II GNEC patients. The proposed nomogram exhibited excellent prediction ability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03029-2. |
format | Online Article Text |
id | pubmed-10163728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101637282023-05-07 De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis Du, Danwei Xie, Yangyang Li, Xiaowen Ni, Zhongkai Shi, Jinbo Huang, Hai World J Surg Oncol Research BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kaplan–Meier survival analyses, propensity score matching (PSM), and competing risk analyses. The predictive nomogram was then built and validated. RESULTS: Four hundred four patients with stage I–II GNEC were enrolled from the SEER database while 28 patients from Hangzhou TCM Hospital were identified as the external validation cohort. After PSM, similar 5-year cancer-specific survival was observed in two groups. The outcomes of competing risk analysis indicated a similar 5-year cumulative incidence of cancer-specific death (CSD) between the two cohorts (35.4% vs. 31.4%, p = 0.731). And there was no significant relation between chemotherapy and CSD in the multivariate competing risks regression analysis (HR, 0.79; 95% CI, 0.48–1.31; p = 0.36). Furthermore, based on the variables from the multivariate analysis, a competing event nomogram was created to assess the 1-, 3-, and 5-year risks of CSD. The 1-, 3-, and 5-year area under the receiver operating characteristic curve (AUC) values were 0.770, 0.759, and 0.671 in the training cohort, 0.809, 0.782, and 0.735 in the internal validation cohort, 0.786, 0.856, and 0.770 in the external validation cohort. Furthermore, calibration curves revealed that the expected and actual probabilities of CSD were relatively consistent. CONCLUSION: Stage I–II GNEC patients could not benefit from adjuvant chemotherapy after surgery. De-escalation of chemotherapy should be considered for stage I–II GNEC patients. The proposed nomogram exhibited excellent prediction ability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03029-2. BioMed Central 2023-05-06 /pmc/articles/PMC10163728/ /pubmed/37149679 http://dx.doi.org/10.1186/s12957-023-03029-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Du, Danwei Xie, Yangyang Li, Xiaowen Ni, Zhongkai Shi, Jinbo Huang, Hai De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title | De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title_full | De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title_fullStr | De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title_full_unstemmed | De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title_short | De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis |
title_sort | de-escalating chemotherapy for stage i–ii gastric neuroendocrine carcinoma? a real-world competing risk analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163728/ https://www.ncbi.nlm.nih.gov/pubmed/37149679 http://dx.doi.org/10.1186/s12957-023-03029-2 |
work_keys_str_mv | AT dudanwei deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis AT xieyangyang deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis AT lixiaowen deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis AT nizhongkai deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis AT shijinbo deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis AT huanghai deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis |